Trial Profile
Phase IIa trial of IVA337 in patient with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs Lanifibranor (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Inventiva Pharma
- 17 Apr 2016 Results presented at The International Liver Congress 2016
- 14 Aug 2015 According to Inventiva Pharmaceuticals media release, company announced there were dose-related changes in biomarkers of insulin resistance, insulin secretion and lipids.
- 14 Aug 2015 New trial record